Ariad Gets First Foreign Patents in Europe, Japan

Jun 15, 2000

Premium

CAMBRIDGE, Mass.--Ariad Pharmaceuticals has been granted its first foreign patents--in Europe and Japan. They cover novel genes that encode for proteins that bind to Ariad’s small-molecule drugs and control cellular activity through regulated gene transcription and protein secretion.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Suspect Confesses in Killing of Developmental Biologist

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

Concerning Links

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

For Coverage

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

PNAS Studies Tackle Syndromic Craniosynostosis, Colorectal Cancer Drivers, More

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.

Featured White Papers

BlueBee Data Security & Compliance

Whole Genome Sequencing of Microbial Communities for Scaling Microbiome and Metagenomic Studies

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Powerful Bioinformatic Support for Specialized Therapeutic Antibody Discovery

Aug

22

Featured Webinar

Biobanks and the Rise of Precision Medicine: Lessons from the Estonian Biobank

This webinar will discuss how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.

Sep

18

Featured Webinar

Highly Sensitive Structural Variant Detection for Medical Genetics: A Comparison to the Standard of Care

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Menu